This result is consistent with Chen et al. (2013), who proposed ZEB1 as a potential therapeutic target and risk factor for cervical cancer in pelvic LNM.22 ZEB1 expression was lowest at 33% in stage II and absent in stage I, with the highest percentages occurring in stages IV at 100% and in III at 90%. This evidence concerns the gene ZEB1 and cervical carcinoma.